This volume of Energy Balance and Cancer provides state-of-the-art descriptions of the rapidly evolving science of epigenetics and how it may explain mechanisms by which alterations in energy balance such as obesity and physical activity may impact cancer. In addition to chapters explaining the processes mediating epigenetic regulation, the volume contains a series of chapters explaining how environmental influences including early life events, nutrition, exercise and microbiota may induce epigenetic changes that can affect carcinogenesis. The following chapters describe epigenetic relations of energy balance to cancer in distinct organ systems including esophagus, colon, prostate and breast. Epigenetics, Energy Balance and Cancer provides a valuable resource for students, research investigators and clinicians seeking to better understand these processes as well as a basis for novel translational and transdisciplinary approaches to further elucidate these processes and develop preventive and therapeutic strategies.

A multidisciplinary approach to the problems related to the diagnosis, treat ment, and rehabilitation of patients with oral cancer and precancer is reflected in the various specialties of the authors who contributed to this book. Today, patients with tumors of the oral cavity are dealt with preferably by a team of specialists who have been properly trained in the field of oncology, who have learned to appreciate each other's knowledge and experience, and who are able to operate as an integrated team. This book is intended for use by every physician and dentist involved in the diagnosis and management of oral cancer. It is 'presented in such a way as to be useful for both the physician in training as well as the specialist in the field of head and neck oncology. The text concentrates on the common as well as the unusual aspects. For those who look for more detailed information, an exten sive list of references is provided at the end of each chapter. It should be emphasized that treatment policies may vary not only in differ ent parts of the world, but also from institution to institution, depending on the expertise of the members of the oncologic team and the available facilities. I. VAN DER W AAL AND G. B. SNOW, editors."

Hematologist/oncologists rely heavily upon the discipline of hematopathology for the care and management of their patients. Whether interpreting a lymph node or bone marrow biopsy, directing a high throughput automated hematology laboratory, or translating testing modalities from the research bench to the clinical laboratory, hematopathologists and other laboratory medicine specialists provide a steady stream of critical data for the clinical practitioner. Recently the rapid advances in diagnosis and treatment of hematological disorders including the need to evaluate patients' eligibility for and monitor responses to rapidly evolving targeted therapies have made the close collaboration between pathologists and clinician practitioners even more essential. Our goal is to provide outstanding reviews of selected topics in hematopathology in a format that provides both general and historical background, as well as an overview of the state-of-the-art in diagnostic hematopathology, with an eye on future potential and future developments.

Proteomics: A Promising Approach for Cancer Research provides an updated overview of scientific knowledge, achievements and findings in the field of cancer proteomics. The book discusses topics such as the use of proteomics in cancer biology and drug discovery, its role in surgical oncology, applications of mass spectrometry, target proteomics, single-cell proteomics, and next-generation proteomics. In addition, it discusses proteomics and phosphor-proteomics in cancer precision medicine; translation of proteomics research into clinical application; and challenges and future developments of the field. This will be a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of proteomics in cancer research and treatment. The field of cancer proteomics is very dynamic, with emerging trends related to clinical solutions developed in recent years, therefore this book's content helps readers get up-to-speed on the topic to easily apply learnings into their research or clinical practice.

This detailed volume explores numerous methods used in basic science laboratories to characterize cancer-related biomarkers, vital for better managing cancer burden, including cancer risk assessment, cancer diagnosis, determining cancer progression, and therapeutic response. From a radiography method to an examination of single-cell RNA-seq and computational analysis tools in cancer research, this book delves into many techniques that could provide valuable molecular information about the tumor and its microenvironment components. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Cancer Biomarkers: Methods and Protocols offers researchers multiple helpful ways to study cancer-associated molecular biomarkers.

This is the third volume on gastrointestinal cancer of the Cancer Treatment and Research Series. The emphasis in this volume is to present a series of papers on areas of high clinical relevance in malignant diseases of the gut. As in the first and second volumes of this series, authors have been selected for their expertise and national and international prominence in their fields. This volume is organized so that papers explaining basic science pro spec tives proceed those dealing with clinical aspects of gastrointestinal cancer. It is clear that in many instances advances gastrointestinal carcinoma cannot be effectively treated if ' cure' is the desired goal. When faced with poorly treatable diseases it is obviously important to look toward the causes and prevention of these illnesses. For this reason, there are several chapters in this volume that examine the issue of carcinogenesis of gastrointestinal cancer. Likewise, in diseases that are poorly treatable in advances stages, one is interested in early detection. Thus, early screening of populations becomes important and is dealt with in three papers in this volume. Chapt ers on treatment explore innovative approaches to therapy of gastrointesti nal cancer. Second-look surgery with resection, arterial perfusion with che motherapy, adjuvant therapy and neoadjuvant therapy are all addressed in various chapters in this volume. Finally, four chapters deal with unusual problems in gastrointestinal cancer. These papers include discussions ofpri mary hepatobillary cancer, lymphoma of the gut, and gastrointestinal endo crine tumors."

The role of carcinogenic agents in the deveolopment of human cancers is now being defined using a variety of human cells as experi mental model systems. A workshop on "neoplastic transformation in human cell systems in vitro: mechanisms of carcinogenesis" was held at the Georgetown University Medical Center, Washington, DC, on April 25-26, 1991. The aims of the workshop were to present the state-of-the art in the transformation of human cells in culture, as well as to provide insight into the molecular and cellular changes involved in the conver sion of normal cells to a neoplastic state of growth. The following topics were closely related to the theme of the workshops: 1. Derivation of in vitro model systems (epithelial, fibroblastic, and hematopoietic). 2. Factors modulating cellular transformation. 3. Usefulness of defined in vitro model systems for viral, chemical, and radiation carcinogenesis. 4. Multistep nature of human cell carcinogenesis. 5. Role of activated and suppressor oncogenes in neoplastic trans formation. The workshop was organized by J. S. Rhim and A. Dritschilo (cochairmen), G. Jay, J. little, M. McCormick, R Tennant, and R R Weischelbaum. There were 32 speakers, 30 poster presentations, and about 190 participants."

Taken together the data presented in this review, and work by many other investigators, support the notion that DNA excision repair is important in a tumor cell's resistance to platinum compounds. Inhibition of this repair system by combination chemotherapy with the excision repair inhibitors HU and Ara-C produces synergistic cell kills and increased levels and persistance of DNA interstrand crosslinks. The studies with cis-DDP and -DDP in combination with UV induced thymine dimers suggest that there may be competition for DNA repair enzymes between the dimer and the platinum lesion. Whether the competing lesion is an intrastrand crosslink, interstrand crosslink, or platinum monoadduct (or all of these lesions) cannot be determined. The similarity between an intrastrand crosslink and a cyclobutane dimer suggests that these lesions may compete for repair. However, the increased peak levels of interstrand crosslinks, and increased persistence of these lesions at later time points suggest that this lesion may also be a substrate for the repair system. These observations may be of clinical relevance. Recently Dr. Kathy Albain of our institution has completed a Phase III I study using a 12 hour pretreatment with HU and Ara-C in patients prior to their cis-DDP therapy. She observed a significant number of responders in this trial (54). She is currently completing a second Phase IIII study substituting IV HU for the oral formulation. We anticipate initiating other clinical trials based upon these observations."

Stephen P. Ethier and a panel of leading investigators comprehensively analyze the cellular, molecular, and endocrine factors in the development of cancers of the breast, prostate, endometrium, and ovary. Concentrating on defining the most important unresolved issues in the field, the authors review how steroid hormones function to regulate normal mammary gland homeostasis in humans, with particular emphasis on the roles of estrogen, progesterone, and growth factors. Comprehensive and up-to-date, Endocrine Oncology offers both basic and clinical researchers not only the latest molecular and cellular findings on endocrine cancers, but also a powerful critical analysis that will prove invaluable to all endocrinologists and oncologists working in the area today.

Energy Balance and Cancer, Epidemiology and Overview is the first in a series of monographs to address the multiple facets of the world wide pandemic of overweight and obesity and its relation to cancer. This volume, authored by leading experts in their perspective fields, provides a broad and comprehensive overview of the problem from the epidemiologic viewpoint with focus on both general and special populations as well as a description of potential molecular mechanisms and reviews of the latest studies of factors impacting the association of energy balance and cancer including the effects of genetics, caloric restriction, exercise, behavior and the built environment. The collected chapters and the authors contributing to this initial volume represent a transdisciplinary approach to analyze and develop novel approaches to understand and solve what, up to now, is a globally refractory problem. The book is written to be understandable and informative to individuals from all concerned disciplines. It should serve to orient students, investigators, nutritionists, public health officials, community planners, clinicians and policy makers to the extent of the problem, its multiple dimensions and potential approaches for research and corrective interventions.

"Apoptosome" is the first book that presents a concise synthesis of recent developments in the understanding of how the activation of the cell death cascade is handled by a cytosolic signalling platform known as the apoptosome.

The book also discusses how insights into the regulation of apoptosome may be exploited for designing new drugs aimed at interfere with a plethora of pathogenetic processes involved in human diseases.

The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatment of diseases associated with apoptosis.

This book will be a valuable resource for researchers investigating the role of apoptosome-dependent cell death in cancer and other diseases, for researchers investigating the molecular mechanism of chemotherapeutic agents and drug-resistance and for physicians using chemotherapeutic agents. Additionally, this book will be an important educational source for PhD students and MD students specializing in molecular and cell biology, and to anybody interested in science, medicine, as well as in recent developments of the ideas and concepts of the molecular biology of programmed cell death.

This second edition provides an overview of recent developments and approaches used by researchers to investigate the properties and functions of mammary epithelial and stem cells, which will contribute to understand the heterogeneity of the mammary gland and of breast cancer. Chapters detail processes used to characterize stem cells, single cell RNA sequencing, computational methods, sophisticated imaging techniques, and a variety of model systems, among others. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Mammary Stem Cells: Methods and Protocols, Second Edition aims to make available protocols used to navigate the intricate behavior of mammary stem cells and to gain further knowledge to take us closer to the design of innovative strategies to prevent and treat breast cancer.

"Healing With Words: A Writer's Cancer Journey" is a compassionate and wry self-help memoir written by an award-winning prolific author, nurse and poet, who at the age of forty-seven found her life shattered first by a DCIS (early breast cancer) diagnosis and five years later by another, seemingly unrelated and incurable cancer--multiple myeloma. The book includes the author's experiences, reflections, poetry and journal entries, in addition to writing prompts for readers to express their own personal story. Raab's journals have provided a safe haven and platform to validate and express her feelings. Raab views journaling to be like a daily vitamin--in that it heals, detoxifies and is essential for optimal health.
Readers will learn to: Understand the importance of early cancer detection and how to take control of their own health Discover the power of writing to release bottled-up emotions Learn how the process of journaling can facilitate healing See how a cancer diagnosis can be a riveting event which can renew and change a person in a unique way
Praise for Raab's "Healing With Words":
"One woman's story, beautifully told and inspiring to those for whom journaling will ease a cancer diagnosis."
--Barbara Delinsky, author UPLIFT: Secrets from the Sisterhood of Breast Cancer Survivors
"Time after time, Diana articulates incisively the thoughts and feelings that convey hoped-for meaning and encouragement. She is a woman who knows what it is to live fully in the face of mortality. She will add value to the life of every person who reads this book. Healing With Words resonates at a spiritual level for me."
--Sena Jeter Naslund, author of Ahab's Wife and Abundance: A Novel of Marie Antoinette
Author's proceeds from the sale of this book donated to benefit the Mayo Clinic Foundation
Learn more at www.DianaRaab.com
Another inspirational book from Loving Healing Press www.LovingHealing.com
HEA039031 Health & Fitness: Diseases - Breast Cancer
SEL501000 Self-Help: Journal Writing
MED058160 Nursing - Oncology & Cancer

This volume provides an overview on the influence of Extracellular Matrix (ECM) on tumor progression. It covers topics such as signaling induced by structural ECM proteins including collagen and fibronectin, the control of ECM deposition and the turnover in tumors. Also discussed are the migration of cells through basement membranes and the function of proteoglycans including lumican and veriscan in tumor progression. Biomaterial-based in-vitro models as well as C. elegans models of the tumor microenvironment are used to show how these models can lead to a greater understanding of the disease mechanisms that promote cancer progression. The book addresses researchers working on cancer biology or ECM, and oncologists alike.

In Tumor Targeting in Cancer Therapy, Dr. Michel Page and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand.

Colorectal cancer has for more than two decades served as the paradigm for the multi-step concept of cancer initiation and progression. Perhaps more than any other organ site, cancer of the colon is extensively characterized at the molecular level. We are now entering a time when molecular classification, rather than histologic classification, of cancer subtypes is driving the development of clinical trials with emerging targeted therapies. The book will focus on the progression from the identification of mutations that drive colorectal cancer initiation and progression to the search for novel therapies to treat the disease.

Infection with the human immunodeficiency virus (HIV) and human T-cell lymphotropic virus type I (HTLV-I) is known to be associated with an increased risk of neoplastic disorders, especially Kaposi's sarcoma and aggressive B-cell lymphoma for the former, and T-cell lymphoma for the latter. The information obtained from the study of these infections has led to remarkable advances in our understanding of the immune system, as well as the biology of human neoplasms. The management of malignant diseases in such patients also poses substantial challenges to clinicians. This book provides an overview of the epidemiology, biology, clinical features, and clinical management of neoplasms occurring in such individuals. It is an important resource for clinicians treating these diseases, and for basic scientists who have an interest in this field.

Prostaglandins, Leukotrienes, and Cancer is a multi-volume series that will focus on an emerging area of cancer research. In 1968, R.H. Williams first reported that elevated prostaglandin levels are present in human medullary car- cinoma. Since that time, the concept that arachidonic acid metabolites may be in- volved in cancer has expanded to include every aspect of the disease from cell transformation through metastasis. Prostaglandins and leukotrienes are generic terms used to describe a family of bioactive lipids produced from unsaturated fatty acids (principally from arachidonic acid) via the cyclooxygenase and lipoxygenase pathways, respec- tively. Cyclooxygenase products consist of diverse products such as prosta- glandin E2 (POE ), prostacyclin (POI ) and thromboxane A2 (TXA ), whereas 2 2 2 lipoxygenase products consist of hydroperoxy fatty acids and mono-, di- and tri-hydroxy acids including leukotrienes. The precursor fatty acids for the cyclooxygenase and lipoxygenase pathways are present in cellular phospholipids. This finding established an important control point in their biosynthesis-the release of substrate. This occurs in response to numerous stimuli that act at the cell surface. Dr. Bengl Samuelsson's extensive study of the metabolism of pros- taglandins indicated that they are rapidly inactivated on a single pass through pulmonary circulation. Thus, they cannot act as circulating hormones and appear to be made on demand in or in the vicinity of target tissues leading to the concept that prostaglandins are local hormones or autocoids.

This textbook discusses the systemic consequences of cancer, covering a range of topics from tumor-promoting systemic effects to the development of cachexia, as summarized in the introductory chapter 1. Part I of this textbook focuses on tumor-promoting systemic effects and begins with a chapter on how tumor-derived extracellular vesicles and particles lay the foundation for future metastases (Chapter 2). Chapter 3 discusses how metastatic cells that have colonized the bone impact the local bone microenvironment, neighboring muscles, and host physiology. Chapter 4 summarizes the available strategies for targeting metastatic cancer and emphasizes the need to incorporate a systemic view of the disease. Following this overview of the systemic effects of cancer progression, Part II of the textbook discusses cancer-induced cachexia, a debilitating systemic effect of advanced cancer. Chapters 5-7 examine the key signaling pathways (interleukin-6/GP130, NF-kB, and muscle proteolysis) that drive the development of cancer cachexia. Chapters 8 and 9 in Part III of this textbook explore how toxicities from anti-cancer therapy are associated with the onset of cachexia in cancer patients, and provide insight into potential approaches to simultaneously target both cancer and cachexia. Chapters 10 and 11 (Part IV) conclude this textbook by outlining promising approaches for the diagnosis and treatment of cachexia as well as strategies to prevent the development of cachexia through exercise. An understanding of the systemic effects of cancer is essential for the design of effective anti-cancer and anti-cachexia treatment strategies. As such, this textbook provides key information for both students and scientists engaged in cancer research and oncology.

Sphingolipids are lipid components of the plasma membrane of eukaryotic cells with an important function in signaling mechanisms in the cell. This book provides insight into the physiological and pathophysiological role of sphingolipids and in particular its derivative ceramide. The function of Sphingolipids in cell signaling with regard to infectious and lung diseases, cancer, cardiovascular diseases and neuropsychiatric disorders are described and treated in distinct parts. Together with Volume 215 from the same Editors, the collection represents a unique, comprehensive work on Sphingolipids, providing information on both: Sphingolipid basic biology as well as its important function in a (patho)physiological context. The book is written for scientists in pharmacology, biochemistry and cell biology with a focus on biomedical research as well as for clinicians in pharmacology, oncology, cardiology, neurology and infectious disease. "

This book provides the readers with an overview of research on p53, which has been shown to play a role in numerous crucial biological pathways in normal and cancer cells. Leading scientist in the field, who have all made direct contributions to the understanding of the molecular events underpinning p53 function, have been invited to contribute the various chapters, which discuss the current knowledge of the signaling cascades that are activated by mutations in p53 and overexpression of MDM2, frequently found in human cancer and are major causes of oncogenesis.

This book features chapters on the molecular basis of oncogenesis induced by gain of function mutation of p53, signaling pathways induced by MDM2 overexpression, control of mutant or wild-type p53 function by MDM2 and MDMX, p53 mutation in hereditary cancer and structural aspects that activate mutant p53 which can be targeted by drug therapy. This book should be useful for scientists at all levels.

These proceedings emanate from the Second Prouts Neck Conference on prostate cancer held on October 17-19, 1986, the theme of which was treat ment, with focus on current issues and future research that is needed to answer critical questions related to optimal management of the various stages of prostate cancer. The objective was to reveal the most crucial problems impeding progress and to crystallize the combined multidisci plinary input generated by the conference into focused concepts or recommendations for presentation to the National Cancer Institute (NCI), with the ultimate intent of targeting research to address the priority issues identified. In organizing the workshop, every effort was made to maintain a multidisciplinary balance among nationally renowned authorities on prostate cancer. Thus, leading surgeons, radiation and medical onco logists and biostatisticians were in equal presence. While there were spirited exchanges with careful scrutiny and critique of all data pre sented, there was a common belief that the challenge of prostate cancer would be best approached in this multidisciplinary Organ Systems-oriented fashion. During the course of the conference, it became apparent to all present that major nomenclature and procedural barriers have made it generally difficult, and frequently impossible, to compare results of clinical research."

Since the advent of hybridoma technology more than two decades ago, numerous antibodies have entered the clinical setting as potent therapeutic agents. Their repeated application in humans, however, is limited by the development of human antimouse antibodies (HAMA) in the recipient, leading to allergic re- tions against the foreign murine protein and rapid neutralization. To circumvent these limitations many new antibodies have recently been tailored through recombinant antibody technology. The initial clinical data show encouraging results, thus demonstrating the potential of these new therapeutic agents. The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is pri- rily addressed to scientists working on recombinant antibodies as well as cli- cians involved with antibody-based therapies. As with other volumes of this series, we placed the main focus on providing detailed protocols describing procedures step-by-step. Moreover, each protocol supplies a troubleshooting guide containing detailed information on possible problems and hints for pot- tial solutions. Antibody technology is a subject of constant and rapid change. This volume, therefore, does not attempt to cover all possible current experimental approaches in the field. Rather, we present carefully selected protocols, written by competent authors who have successfully verified the particular method described. Given our own professional backgrounds and interest in oncology, we chose to conc- trate chiefly on therapeutic agents for cancer patients.